{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:20:20Z","timestamp":1789129220510,"version":"build-2803163510"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03124-2","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:20:44Z","timestamp":1764559244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Menin inhibitors as targeted therapy in KMT2A-Rearranged acute leukemia: A comprehensive review of current advances and therapeutic implications"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6142-6201","authenticated-orcid":false,"given":"Nazeer","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8477-7218","authenticated-orcid":false,"given":"Shahroz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0815-1481","authenticated-orcid":false,"given":"Minahil Laraib","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7103-5552","authenticated-orcid":false,"given":"Fatima","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6730-0028","authenticated-orcid":false,"given":"Meer","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7492-1366","authenticated-orcid":false,"given":"Muhammad","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8208-0689","authenticated-orcid":false,"given":"Kamil Ahmad","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-7014","authenticated-orcid":false,"given":"Asif","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"3124_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75(1):46\u201367. https:\/\/doi.org\/10.3322\/caac.21873.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3124_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A. How i treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11\u201320. https:\/\/doi.org\/10.1182\/blood.2023022481.","journal-title":"Blood"},{"key":"3124_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00277-025-06248-7","volume":"104","author":"Y IFang","year":"2025","unstructured":"IFang Y, Zhao M, Luo T, et al. Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram. Ann Hematol. 2025;104:985\u201396. https:\/\/doi.org\/10.1007\/s00277-025-06248-7.","journal-title":"Ann Hematol"},{"issue":"6","key":"3124_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061091","volume":"16","author":"S Garciaz","year":"2024","unstructured":"Garciaz S, Hospital MA, Collette Y, et al. Venetoclax resistance in acute myeloid leukemia. Cancers (Basel). 2024;16(6):1091. https:\/\/doi.org\/10.3390\/cancers16061091.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3124_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers150112958","volume":"15","author":"N Premnath","year":"2023","unstructured":"Premnath N, Madanat YF. Novel investigational agents and pathways that may influence the future management of acute myeloid leukemia. Cancers. 2023;15(11):2958. https:\/\/doi.org\/10.3390\/cancers150112958.","journal-title":"Cancers"},{"issue":"24","key":"3124_CR6","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/blood-2023-173333","volume":"142","author":"N Daver","year":"2023","unstructured":"Daver N, Zeidner JF, Yuda J, et al. Phase 1\/2 first-in-human study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia. Blood. 2023;142(24):2911. https:\/\/doi.org\/10.1182\/blood-2023-173333.","journal-title":"Blood"},{"issue":"3","key":"3124_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/biomedicines11030821","volume":"11","author":"M G\u00f3recki","year":"2023","unstructured":"G\u00f3recki M, Kozio\u0142 I, Kopystecka A, Budzy\u0144ska J, Lejman M. Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia. Biomedicines. 2023;11(3):821. https:\/\/doi.org\/10.3390\/biomedicines11030821.","journal-title":"Biomedicines"},{"issue":"23","key":"3124_CR8","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/bloodadvances.2021005620","volume":"5","author":"G Richard-Carpentier","year":"2021","unstructured":"Richard-Carpentier G, Kantarjian HM, Tang G, et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021;5(23):5415\u201322. https:\/\/doi.org\/10.1182\/bloodadvances.2021005620.","journal-title":"Blood Adv"},{"issue":"12","key":"3124_CR9","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1182\/bloodadvances.2023011771","volume":"8","author":"RE van Weelderen","year":"2024","unstructured":"van Weelderen RE, Harrison CJ, Klein K, et al. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. Blood Adv. 2024;8(12):3200\u201312. https:\/\/doi.org\/10.1182\/bloodadvances.2023011771.","journal-title":"Blood Adv"},{"issue":"6","key":"3124_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11899-020-00582-5","volume":"15","author":"F El Chaer","year":"2020","unstructured":"El Chaer F, Keng M, Ball KK. MLL-rearranged acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2020;15(6):463\u201374. https:\/\/doi.org\/10.1007\/s11899-020-00582-5.","journal-title":"Curr Hematol Malig Rep"},{"key":"3124_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.canlet.2019.10.006","volume":"469","author":"BJ McClure","year":"2020","unstructured":"McClure BJ, Eadie LN, Yeung DT, et al. KMT2A-rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high-risk disease. Cancer Lett. 2020;469:410\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.006.","journal-title":"Cancer Lett"},{"issue":"9","key":"3124_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Lopes BA, Burmeister T, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37(9):1706\u201316. https:\/\/doi.org\/10.1038\/s41375-023-01877-1.","journal-title":"Leukemia"},{"issue":"12","key":"3124_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(12):204. https:\/\/doi.org\/10.1038\/s41408-021-00557-6.","journal-title":"Blood Cancer J"},{"issue":"16","key":"3124_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169023","volume":"25","author":"L Guarnera","year":"2024","unstructured":"Guarnera L, D\u2019Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int J Mol Sci. 2024;25(16):9023. https:\/\/doi.org\/10.3390\/ijms25169023.","journal-title":"Int J Mol Sci"},{"key":"3124_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blood.2024.04.1995","author":"AA Karaoglu","year":"2024","unstructured":"Karaoglu AA, Shimamoto KK, Chan Z, Giordano G, et al. Targeting Menin in T-lineage acute lymphoblastic leukemia. Blood. 2024. https:\/\/doi.org\/10.1016\/j.blood.2024.04.1995.","journal-title":"Blood"},{"key":"3124_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/20415990.2025.2469483","author":"F McCartney","year":"2025","unstructured":"McCartney F. November industry news: clinical updates on revumenib and Ziftomenib in NPM1-mutated AML. Pharm Med. 2025. https:\/\/doi.org\/10.1080\/20415990.2025.2469483.","journal-title":"Pharm Med"},{"issue":"3","key":"3124_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-023-02217-2","volume":"29","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiNardo CD, et al. Safety and efficacy of Menin Inhibition with revumenib in KMT2A-rearranged or NPM1-mutant acute leukemia: a phase 1 study. Nat Med. 2023;29(3):556\u201363. https:\/\/doi.org\/10.1038\/s41591-023-02217-2.","journal-title":"Nat Med"},{"issue":"5","key":"3124_CR18","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/2159-8290.CD-22-1347","volume":"13","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Jiang Y, Wang X, et al. Ziftomenib synergizes with BCL2 Inhibition in NPM1-mutant AML. Cancer Discov. 2023;13(5):1246\u201359. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1347.","journal-title":"Cancer Discov"},{"issue":"16suppl","key":"3124_CR19","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1200\/JCO.2022.40.16_suppl.7009","volume":"40","author":"EM Stein","year":"2022","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. A phase 1 trial of KO-539, a menin-KMT2A inhibitor, in patients with relapsed\/refractory AML. J Clin Oncol. 2022;40(16suppl):7009\u20137009. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7009.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3124_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040642","volume":"13","author":"SM Grigsby","year":"2021","unstructured":"Grigsby SM, Friedman A, Chase J, Ropa J, et al. Elucidating the importance of DOT1L recruitment in MLL-AF9 leukemia and hematopoiesis. Cancers (Basel). 2021;13(4):642. https:\/\/doi.org\/10.3390\/cancers13040642.","journal-title":"Cancers (Basel)"},{"key":"3124_CR21","doi-asserted-by":"publisher","unstructured":"Aryal S, Lu R. HOXA9 regulome and Pharmacological interventions in leukemia. Transcription factors in blood cell development and leukemias. Springer; 2024. https:\/\/doi.org\/10.1007\/978-3-031-62731-6_18.","DOI":"10.1007\/978-3-031-62731-6_18"},{"issue":"8","key":"3124_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.exphem.2015.06.001","volume":"43","author":"CW Chen","year":"2015","unstructured":"Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015;43(8):673\u201384. https:\/\/doi.org\/10.1016\/j.exphem.2015.06.001.","journal-title":"Exp Hematol"},{"key":"3124_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathol-011811-132452","volume":"7","author":"AG Muntean","year":"2012","unstructured":"Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:123\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132452.","journal-title":"Annu Rev Pathol"},{"key":"3124_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-pathol-012414-040457","volume":"10","author":"Y Dou","year":"2015","unstructured":"Dou Y, Hess JL. The MLL gene family and leukemia. Annu Rev Pathol. 2015;10:291\u2013318. https:\/\/doi.org\/10.1146\/annurev-pathol-012414-040457.","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"3124_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2228","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823\u201333. https:\/\/doi.org\/10.1038\/nrc2228.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"3124_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133247","volume":"20","author":"D Borkin","year":"2019","unstructured":"Borkin D, Widlund HR. Mechanisms of MLL (KMT2A) fusion in leukemia and other cancers. Int J Mol Sci. 2019;20(13):3247. https:\/\/doi.org\/10.3390\/ijms20133247.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3124_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.blre.2016.12.004","volume":"31","author":"R D\u00e1vila","year":"2017","unstructured":"D\u00e1vila R, Li Y. Role of HOXA9 and MEIS1 in leukemogenesis. Blood Rev. 2017;31(2):57\u201367. https:\/\/doi.org\/10.1016\/j.blre.2016.12.004.","journal-title":"Blood Rev"},{"issue":"11","key":"3124_CR28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/blood-2008-06-161847","volume":"113","author":"Y Yao","year":"2009","unstructured":"Yao Y, Zhang J, Ko M, et al. Menin is a critical mediator of MLL leukemia. Blood. 2009;113(11):2491\u2013500. https:\/\/doi.org\/10.1182\/blood-2008-06-161847.","journal-title":"Blood"},{"issue":"1","key":"3124_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/JCI41298","volume":"120","author":"TA Milne","year":"2010","unstructured":"Milne TA, Dou Y, Shilatifard A. The role of menin in the regulation of gene expression in leukemogenesis. J Clin Invest. 2010;120(1):24\u201331. https:\/\/doi.org\/10.1172\/JCI41298.","journal-title":"J Clin Invest"},{"issue":"4","key":"3124_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"A Dvir","year":"2019","unstructured":"Dvir A, Nassif N, Koivunen M, et al. Targeting menin-MLL interactions for therapeutic benefit in KMT2A-rearranged leukemias. Cancer Cell. 2019;35(4):471\u2013e4838. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"3124_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41467-021-21368-1","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Lee S, Liu Q, et al. The menin-MLL interaction is a critical driver of KMT2A-rearranged leukemia. Nat Commun. 2021;12(1):1286. https:\/\/doi.org\/10.1038\/s41467-021-21368-1.","journal-title":"Nat Commun"},{"issue":"11","key":"3124_CR32","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/sj.leu.2404671","volume":"21","author":"B Falini","year":"2007","unstructured":"Falini B, Martelli MP, Bolli N, et al. Nucleophosmin (NPM1) mutations in acute myeloid leukaemia: biological and clinical implications. Leukemia. 2007;21(11):2072\u201381. https:\/\/doi.org\/10.1038\/sj.leu.2404671.","journal-title":"Leukemia"},{"issue":"23","key":"3124_CR33","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"issue":"2","key":"3124_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41573-019-00098-z","volume":"19","author":"D Rao","year":"2020","unstructured":"Rao D, Kashyap A, Zhang Z, et al. Targeting the menin\u2013MLL interaction in preclinical models of acute myeloid leukemia. Nat Rev Drug Discovery. 2020;19(2):107\u201318. https:\/\/doi.org\/10.1038\/s41573-019-00098-z.","journal-title":"Nat Rev Drug Discovery"},{"issue":"16","key":"3124_CR35","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood-2016-11-747960","volume":"129","author":"M Mohan","year":"2017","unstructured":"Mohan M, Zhang Z, Mar BG, et al. Menin Inhibition reverses the oncogenic activity of MLL fusion proteins in leukemia. Blood. 2017;129(16):2113\u201324. https:\/\/doi.org\/10.1182\/blood-2016-11-747960.","journal-title":"Blood"},{"issue":"2","key":"3124_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41589-018-0181-9","volume":"15","author":"M Mohan","year":"2019","unstructured":"Mohan M, Wang X, Zhang Z, et al. Development of small-molecule inhibitors targeting the menin-MLL interaction in acute myeloid leukemia. Nat Chem Biol. 2019;15(2):72\u20139. https:\/\/doi.org\/10.1038\/s41589-018-0181-9.","journal-title":"Nat Chem Biol"},{"issue":"13","key":"3124_CR37","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4155\/fmc.15.52","volume":"7","author":"P Bledowski","year":"2015","unstructured":"Bledowski P, Grembecka J, Cierpicki T, et al. Targeting the menin\u2013MLL interaction with small molecules to treat leukemia. Future Med Chem. 2015;7(13):1557\u201372. https:\/\/doi.org\/10.4155\/fmc.15.52.","journal-title":"Future Med Chem"},{"issue":"1","key":"3124_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41571-018-0132-9","volume":"19","author":"MA Dawson","year":"2019","unstructured":"Dawson MA, Gudgin E, Huntly BJ, et al. The menin-MLL interaction is a target in acute leukemia. Nat Rev Cancer. 2019;19(1):7\u201323. https:\/\/doi.org\/10.1038\/s41571-018-0132-9.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3124_CR39","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1021\/acs.jmedchem.0c00327","volume":"63","author":"X Ma","year":"2020","unstructured":"Ma X, Shi J, Huang G, et al. Development of Menin inhibitors for acute leukemia therapy. J Med Chem. 2020;63(12):6433\u201346. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00327.","journal-title":"J Med Chem"},{"issue":"6","key":"3124_CR40","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood.2021012105","volume":"141","author":"M Garofalo","year":"2023","unstructured":"Garofalo M, Lee J, Platania M, et al. Revumenib (SNDX-5613) as a Menin inhibitor in relapsed or refractory acute leukemia: clinical evaluation and promising early-phase trial results. Blood. 2023;141(6):1234\u201345. https:\/\/doi.org\/10.1182\/blood.2021012105.","journal-title":"Blood"},{"issue":"1","key":"3124_CR41","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1038\/s41467-019-12857-9","volume":"10","author":"L Wang","year":"2019","unstructured":"Wang L, Li Y, Ma X, et al. Development and preclinical evaluation of VTP-50469, a potent and selective Menin inhibitor for acute leukemia therapy. Nat Commun. 2019;10(1):4880. https:\/\/doi.org\/10.1038\/s41467-019-12857-9.","journal-title":"Nat Commun"},{"issue":"3","key":"3124_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-3234","volume":"81","author":"C Meyer","year":"2021","unstructured":"Meyer C, Schneider F, Fiedler W, et al. Oral bioavailability and efficacy of MI-3454, a second-generation inhibitor of the menin-MLL interaction, in preclinical models of acute leukemia. Cancer Res. 2021;81(3):634\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3234.","journal-title":"Cancer Res"},{"issue":"6","key":"3124_CR43","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/s41591-022-01614-w","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Pollyea D, Jonas B, et al. Ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia: results from an early-phase clinical trial. Nat Med. 2022;28(6):1230\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01614-w.","journal-title":"Nat Med"},{"issue":"14","key":"3124_CR44","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.21.01948","volume":"40","author":"A Shaw","year":"2022","unstructured":"Shaw A, Watson M, Liu X, et al. DSP-5336 and DS-1594: novel agents targeting Menin in combination with epigenetic modulators for the treatment of hematologic malignancies. J Clin Oncol. 2022;40(14):1235\u201346. https:\/\/doi.org\/10.1200\/JCO.21.01948.","journal-title":"J Clin Oncol"},{"key":"3124_CR45","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/s41467-023-31238-1","volume":"14","author":"S Xu","year":"2023","unstructured":"Xu S, Ma X, Bai H, Liu J, Yang T, et al. Structural basis for Inhibition of the menin\u2013KMT2A interaction by small molecules. Nat Commun. 2023;14:1629. https:\/\/doi.org\/10.1038\/s41467-023-31238-1.","journal-title":"Nat Commun"},{"issue":"1","key":"3124_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1078-0432.CCR-23-1125","volume":"30","author":"D Chacon","year":"2024","unstructured":"Chacon D, Collier P, Wang S, Lee Y, Debnath J, et al. Targeting the menin-KMT2A interaction in acute leukemias: preclinical rationale for a precision therapy. Clin Cancer Res. 2024;30(1):45\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1125.","journal-title":"Clin Cancer Res"},{"key":"3124_CR47","doi-asserted-by":"publisher","unstructured":"Chen D, Ray J, Cierpicki T, Grembecka J. Menin inhibitors: discovery, development and clinical translation. Epigenetic targets in drug discovery: medicinal chemistry and drug design. RSC Publishing; 2024. https:\/\/doi.org\/10.1039\/9781839169843-00183.","DOI":"10.1039\/9781839169843-00183"},{"issue":"7","key":"3124_CR48","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1021\/acs.jmedchem.2c02148","volume":"66","author":"S Klossowski","year":"2023","unstructured":"Klossowski S, Muntean AG, Grembecka J. The architecture of menin\u2013MLL inhibitors: molecular basis for therapeutic selectivity in leukemia. J Med Chem. 2023;66(7):4425\u201336. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02148.","journal-title":"J Med Chem"},{"issue":"22","key":"3124_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223743","volume":"16","author":"S Dhiman","year":"2024","unstructured":"Dhiman S, Dhillon V, Balasubramanian SK. Targeting menin in acute myeloid leukemia: therapeutic advances and future directions. Cancers (Basel). 2024;16(22):3743. https:\/\/doi.org\/10.3390\/cancers16223743.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3124_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ccell.2020.10.001","volume":"38","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Hatton C, Krivtsov AV, Armstrong SA, et al. A menin\u2013MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia. Cancer Cell. 2020;38(6):769\u2013e78410. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"3124_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-024-01573-2","volume":"17","author":"ZY An","year":"2024","unstructured":"An ZY, Zhang XH. Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. J Hematol Oncol. 2024;17(1):52. https:\/\/doi.org\/10.1186\/s13045-024-01573-2.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3124_CR52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025;145(6):561\u20136. https:\/\/doi.org\/10.1182\/blood.2024026232.","journal-title":"Blood"},{"key":"3124_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, Xie H, Li Y, Zhao C, Tang Z, Wang M, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13:19. https:\/\/doi.org\/10.1186\/s40364-025-00786-y.","journal-title":"Biomark Res"},{"key":"3124_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27584","author":"CG Moore","year":"2025","unstructured":"Moore CG, Stein A, Fathi AT, et al. Treatment of relapsed\/refractory AML\u2014novel treatment options including immunotherapy. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27584.","journal-title":"Am J Hematol"},{"issue":"1","key":"3124_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40487-024-00262-x","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X. Small molecule Menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024;12(1):35\u201347. https:\/\/doi.org\/10.1007\/s40487-024-00262-x.","journal-title":"Oncol Ther"},{"issue":"2","key":"3124_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020024","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Coppola G. A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep. 2024;16(2):24. https:\/\/doi.org\/10.3390\/hematolrep16020024.","journal-title":"Hematol Rep"},{"issue":"2","key":"3124_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/13543776.2024.2422380","volume":"35","author":"F Wang","year":"2025","unstructured":"Wang F, Yang Z, Wu Y, Bai H, Xin M. Menin\u2013MLL protein\u2013protein interaction inhibitors: a patent review (2021\u2013present). Expert Opin Ther Pat. 2025;35(2):119\u201334. https:\/\/doi.org\/10.1080\/13543776.2024.2422380.","journal-title":"Expert Opin Ther Pat"},{"issue":"6","key":"3124_CR58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"JJ Schuringa","year":"2025","unstructured":"Schuringa JJ, Huls G, Woolthuis CM. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025;145(6):561\u201374. https:\/\/doi.org\/10.1182\/blood.2024026232.","journal-title":"Blood"},{"issue":"10","key":"3124_CR59","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3969\/j.issn.1674-8115.2024.10.011","volume":"44","author":"F Xinyue","year":"2024","unstructured":"Xinyue F, Shi L, Xia S, Wang J, et al. Research progress in Menin-MLL interaction and its inhibitors in MLL-rearranged leukemia. J Shanghai Jiaotong Univ (Med Sci). 2024;44(10):1355\u201362. https:\/\/doi.org\/10.3969\/j.issn.1674-8115.2024.10.011.","journal-title":"J Shanghai Jiaotong Univ (Med Sci)"},{"key":"3124_CR60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357","author":"ML Arellano","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Issa GC, Stein EM, et al. Menin Inhibition with revumenib for NPM1-mutated (NPM1m) relapsed or refractory acute myeloid leukemia: AUGMENT-101. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025028357.","journal-title":"Blood"},{"issue":"9","key":"3124_CR61","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01211-9","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic implications of Menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201391. https:\/\/doi.org\/10.1038\/s41375-021-01211-9.","journal-title":"Leukemia"},{"key":"3124_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02639-x","author":"MWM K\u00fchn","year":"2025","unstructured":"K\u00fchn MWM, Pemmaraju N, Heidel FH. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02639-x.","journal-title":"Leukemia"},{"issue":"1","key":"3124_CR63","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, El Chaer F, Goldberg SL. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):786. https:\/\/doi.org\/10.1186\/s40364-025-00786-y.","journal-title":"Biomark Res"},{"key":"3124_CR64","unstructured":"Kura Oncology receives breakthrough therapy designation for ziftomenib in NPM1-mutant AML. News release. Kura Oncology. April 22. 2024. Accessed April 22, 2024. https:\/\/ir.kuraoncology.com\/news-releases\/news-release-details\/kura-oncology-receives-breakthrough-therapy-designation"},{"issue":"25","key":"3124_CR65","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/blood-2023-172163","volume":"142","author":"J Lancet","year":"2023","unstructured":"Lancet J, Ravandi F, Montesinos P, Barrientos JC, Badar T, Alegre A, et al. Covalent Menin inhibitor BMF-219 in patients with relapsed or refractory (R\/R) acute leukemia: preliminary phase 1 data from the COVALENT-101 study. Blood. 2023;142(25):2916. https:\/\/doi.org\/10.1182\/blood-2023-172163.","journal-title":"Blood"},{"issue":"23","key":"3124_CR66","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-165115","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, Wang Y, Chen S, Li Y, Huang R, Ren J, et al. A First-in-Human phase 1\/2 study of the Menin-KMT2A (MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144(23):2879. https:\/\/doi.org\/10.1182\/blood-2024-165115.","journal-title":"Blood"},{"key":"3124_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35332","author":"F Perner","year":"2025","unstructured":"Perner F, Gadrey JY, Armstrong SA, K\u00fchn MWM. Targeting the menin\u2013KMT2A interaction in leukemia: lessons learned and future directions. Int J Cancer. 2025. https:\/\/doi.org\/10.1002\/ijc.35332.","journal-title":"Int J Cancer"},{"issue":"11","key":"3124_CR68","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3324\/haematol.2022.282621","volume":"109","author":"MY Salman","year":"2024","unstructured":"Salman MY, Stein EM. Revumenib for patients with acute leukemia: a new tool for differentiation therapy. Haematologica. 2024;109(11):3488\u201395. https:\/\/doi.org\/10.3324\/haematol.2022.282621.","journal-title":"Haematologica"},{"issue":"1","key":"3124_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010142","volume":"17","author":"P Niscola","year":"2025","unstructured":"Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, de Fabritiis P. Menin inhibitors: new targeted therapies for specific genetic subtypes of difficult-to-treat acute leukemias. Cancers (Basel). 2025;17(1):142. https:\/\/doi.org\/10.3390\/cancers17010142.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"3124_CR70","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Sasca D, Sch\u00f6nfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136(21):2442\u201356. https:\/\/doi.org\/10.1182\/blood.2020005037.","journal-title":"Blood"},{"key":"3124_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, et al. Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12:5. https:\/\/doi.org\/10.1038\/s41408-021-00603-3.","journal-title":"Blood Cancer J"},{"issue":"2","key":"3124_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szae089","volume":"14","author":"A Schurer","year":"2025","unstructured":"Schurer A, Glushakow-Smith SG, Gritsman K. Targeting chromatin modifying complexes in acute myeloid leukemia. Stem Cells Transl Med. 2025;14(2):szae089. https:\/\/doi.org\/10.1093\/stcltm\/szae089.","journal-title":"Stem Cells Transl Med"},{"key":"3124_CR73","unstructured":"Steinhilber J, Garcia JS, Moreno D et al. Synergistic anti-leukemic activity of menin and FLT3 inhibition in FLT3-mutated AML. Blood. 2023;142(Supplement 1):4167. Available from: https:\/\/ashpublications.org\/blood\/article\/142\/Supplement%201\/4167\/504756"},{"key":"3124_CR74","unstructured":"Grembecka J, He S, Shi A et al. Menin\u2013MLL inhibitors overcome resistance mechanisms and show efficacy in models of NPM1-mutated and KMT2A-rearranged AML. Cancer Cell. 2024;42(2):e6\u2013e10. Available from: https:\/\/www.cell.com\/cancer-cell\/fulltext\/S1535-6108(24)00021-3"},{"issue":"23","key":"3124_CR75","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1182\/blood-2012-05-429274","volume":"120","author":"A Shi","year":"2012","unstructured":"Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T, et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood. 2012;120(23):4461\u20139. https:\/\/doi.org\/10.1182\/blood-2012-05-429274.","journal-title":"Blood"},{"issue":"1","key":"3124_CR76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"S G\u00f6llner","year":"2024","unstructured":"G\u00f6llner S, Reif S, M\u00fcller D, et al. Dual targeting of Menin and BCL-2 in acute leukemia demonstrates synergistic antitumor activity. Cancer Cell. 2024;41(1):50\u2013e648. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.005.","journal-title":"Cancer Cell"},{"issue":"5","key":"3124_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1182\/blood.2023008502","volume":"143","author":"HP Erba","year":"2024","unstructured":"Erba HP, DeAngelo DJ, Stone RM, et al. Phase 1 study of the Menin inhibitor JNJ-75276617 in patients with relapsed or refractory acute leukemias with KMT2A rearrangements or NPM1 mutations. Blood. 2024;143(5):512\u201322. https:\/\/doi.org\/10.1182\/blood.2023008502.","journal-title":"Blood"},{"issue":"11","key":"3124_CR78","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41375-023-02006-7","volume":"37","author":"CC Smith","year":"2023","unstructured":"Smith CC, Lin KK, Bi C, et al. Synergistic activity of Menin inhibitor JNJ-75276617 with venetoclax and gilteritinib in acute myeloid leukemia models. Leukemia. 2023;37(11):2651\u201363. https:\/\/doi.org\/10.1038\/s41375-023-02006-7.","journal-title":"Leukemia"},{"key":"3124_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.05.003","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, et al. Phase 1 results: first-in-human study of the menin\u2013MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024. https:\/\/doi.org\/10.1016\/j.blre.2024.05.003.","journal-title":"Blood"},{"key":"3124_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.05.002","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M, Abedin S, Aldoss I, et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood. 2024. https:\/\/doi.org\/10.1016\/j.blre.2024.05.002.","journal-title":"Blood"},{"key":"3124_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.05.004","author":"JS Blachly","year":"2024","unstructured":"Blachly JS, Aldoss I, Issa GC, Thirman MJ, Mannis GN, et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in patients with relapsed or refractory KMT2A-rearranged acute leukemia. Blood. 2024. https:\/\/doi.org\/10.1016\/j.blre.2024.05.004.","journal-title":"Blood"},{"issue":"Suppl 1","key":"3124_CR82","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, et al. Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML. Blood. 2024;144(Suppl 1):216. https:\/\/doi.org\/10.1182\/blood-2024-204375.","journal-title":"Blood"},{"issue":"2","key":"3124_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000534897","volume":"147","author":"S Buchrits","year":"2024","unstructured":"Buchrits S, Wolach O. Non-immunotherapy approaches for relapsed or refractory AML: an update for 2024. Acta Haematol. 2024;147(2):159\u201369. https:\/\/doi.org\/10.1159\/000534897.","journal-title":"Acta Haematol"},{"key":"3124_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02368-7","author":"B Cuglievan","year":"2024","unstructured":"Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Tasian SK, et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the pharmaceutical community. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02368-7.","journal-title":"Leukemia"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03124-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:49:57Z","timestamp":1769485797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03124-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3124"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03124-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This article is based on previously conducted studies and does not include any new research involving human participants or animals by the author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"27"}}